Neuphoria Therapeutics (NEUP) Net Cash Flow (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Net Cash Flow for 4 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 126.71% year-over-year to -$3.4 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 83.04% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, up 280.42% from the prior year.
• Net Cash Flow was -$3.4 million for Q1 2026 at Neuphoria Therapeutics, down from $8.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $12.6 million in Q1 2025 and troughed at -$4.7 million in Q3 2024.
• A 4-year average of $579288.7 and a median of -$1.5 million in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow plunged 306.38% in 2024 and jumped 915.67% in 2025, its largest moves.
• Over 4 years, Net Cash Flow stood at $1.7 million in 2023, then sank by 306.38% to -$3.5 million in 2024, then soared by 337.25% to $8.2 million in 2025, then plunged by 140.93% to -$3.4 million in 2026.
• The last three Net Cash Flow figures came in at -$3.4 million (Q1 2026), $8.2 million (Q4 2025), and -$546385.0 (Q3 2025), per Business Quant data.